不同抗凝水平下各维生素K依赖性凝血因子之间的相互关系。
Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation.
作者信息
Chan E, Aarons L, Serlin M, Breckenridge A, Rowland M
机构信息
Pharmacokinetics Department, University of Manchester.
出版信息
Br J Clin Pharmacol. 1987 Nov;24(5):621-5. doi: 10.1111/j.1365-2125.1987.tb03221.x.
Abstract
- The effect of subtherapeutic doses of warfarin on the activities of the four vitamin K-dependent clotting factors was studied at steady state in five patients each of whom had completed a therapeutic course of anticoagulation. 2. The four clotting factor activities were shown to be depressed to a similar extent for a given dose of warfarin. 3. The prothrombin complex activity was significantly lower than that of any of the clotting factors.
摘要
- 在五名完成抗凝治疗疗程的患者中，研究了亚治疗剂量华法林对四种维生素K依赖性凝血因子活性在稳态时的影响。2. 对于给定剂量的华法林，四种凝血因子活性显示出类似程度的降低。3. 凝血酶原复合物活性显著低于任何一种凝血因子的活性。
相似文献
1
Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation.不同抗凝水平下各维生素K依赖性凝血因子之间的相互关系。
Br J Clin Pharmacol. 1987 Nov;24(5):621-5. doi: 10.1111/j.1365-2125.1987.tb03221.x.
2
The potentiation of warfarin anticoagulation by amiodarone.胺碘酮对华法林抗凝作用的增强作用。
Circulation. 1982 May;65(5):1025-9. doi: 10.1161/01.cir.65.5.1025.
3
The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat.
J Pharmacol Exp Ther. 1992 Mar;260(3):1081-5.
4
Effect of warfarin on the kinetics of the vitamin K-dependent clotting factors in rats.华法林对大鼠维生素K依赖凝血因子动力学的影响。
J Pharmacol Exp Ther. 1977 May;201(2):507-17.
5
The biochemical basis of warfarin therapy.
Adv Exp Med Biol. 1987;214:3-16. doi: 10.1007/978-1-4757-5985-3_2.
6
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.维生素K1 2,3-环氧化物还原酶的抑制与华法林导致的凝血因子活性降低之间的关系。
Br J Clin Pharmacol. 1988 Jan;25(1):1-7. doi: 10.1111/j.1365-2125.1988.tb03274.x.
7
The dose-dependent effect of BHT (butylated hydroxytoluene) on vitamin K-dependent blood coagulation in rats.
Food Chem Toxicol. 1994 Jul;32(7):589-94. doi: 10.1016/0278-6915(94)90001-9.
8
A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.维生素 K 依赖的凝血因子和抗凝蛋白的联合模型。
Clin Pharmacokinet. 2017 Dec;56(12):1555-1566. doi: 10.1007/s40262-017-0541-5.
9
Assessment of thrombogenicity of activated and non-activated prothrombin concentrates in a rat model.在大鼠模型中评估活化和未活化凝血酶原浓缩物的血栓形成倾向。
Br J Exp Pathol. 1986 Aug;67(4):597-604.
10
Anticoagulant effects of warfarin and kinetics of K vitamins in blood and feces.华法林的抗凝作用及血液和粪便中维生素K的动力学
Artery. 1994;21(3):148-60.
引用本文的文献
1
A factor VII-based method for the prediction of anticoagulant response to warfarin.基于因子 VII 的华法林抗凝反应预测方法。
Sci Rep. 2018 Aug 13;8(1):12041. doi: 10.1038/s41598-018-30516-4.
2
Assessment of toxicity and potential risk of the anticoagulant rodenticide diphacinone using Eastern screech-owls (Megascops asio).利用东方角鸮（Megascops asio）评估抗凝杀鼠剂二苯并呋喃的毒性和潜在风险。
Ecotoxicology. 2012 Apr;21(3):832-46. doi: 10.1007/s10646-011-0844-5. Epub 2012 Jan 8.
3
Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.华法林治疗起始阶段国际标准化比值及维持剂量的预测
Br J Clin Pharmacol. 1999 Jul;48(1):63-70. doi: 10.1046/j.1365-2125.1999.00967.x.
4
Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.华法林撤药。药代动力学-药效学考量。
Clin Pharmacokinet. 1996 Apr;30(4):300-13. doi: 10.2165/00003088-199630040-00003.
5
The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat.长期华法林对大鼠实验性静脉和动脉血栓形成的抗凝、抗血栓及出血作用。
Ir J Med Sci. 1996 Jul-Sep;165(3):213-8. doi: 10.1007/BF02940253.
本文引用的文献
1
Substitution therapy in haemophilia B.乙型血友病的替代疗法。
Thromb Diath Haemorrh. 1961 Dec 15;6:391-410.
2
Factor VII; its turnover rate and its possible role in thrombogenesis.凝血因子VII；其周转率及其在血栓形成中的可能作用。
Thromb Diath Haemorrh. 1960 Mar 1;4:196-200.
3
EFFECT OF ORAL ANTICOAGULANTS ON FACTORS VII, IX, X, AND II.口服抗凝剂对因子VII、IX、X和II的影响。
Arch Intern Med. 1965 Jun;115:667-73. doi: 10.1001/archinte.1960.03860180039007.
4
BEHAVIOUR OF FACTORS II, VII, IX AND X IN BLEEDING COMPLICATIONS DURING LONG-TERM TREATMENT WITH COUMARIN.香豆素长期治疗期间出血并发症中凝血因子II、VII、IX和X的行为
Thromb Diath Haemorrh. 1964 Jan 1;10:278-81.
5
THE FATE OF PROTHROMBIN AND FACTORS VIII, IX AND X TRANSFUSED TO PATIENTS DEFICIENT IN THESE FACTORS.凝血酶原以及凝血因子VIII、IX和X输注给缺乏这些因子的患者后的转归
Br J Haematol. 1963 Oct;9:532-47. doi: 10.1111/j.1365-2141.1963.tb05478.x.
6
Turnover of prothrombin, factor VII and factor IX in a patient with hemophilia A.甲型血友病患者凝血酶原、因子 VII 和因子 IX 的周转率。
Scand J Clin Lab Invest. 1961;13:668-72. doi: 10.3109/00365516109137342.
7
A study of a case of congenital hypoprothrombinaemia.
Br J Haematol. 1959 Jul;5:294-301. doi: 10.1111/j.1365-2141.1959.tb04037.x.
8
Interaction between diflunisal and warfarin.双氟尼酸与华法林之间的相互作用。
Clin Pharmacol Ther. 1980 Oct;28(4):493-8. doi: 10.1038/clpt.1980.193.
9
Mechanism of action of vitamin K: synthesis of gamma-carboxyglutamic acid.维生素K的作用机制：γ-羧基谷氨酸的合成
CRC Crit Rev Biochem. 1980;8(2):191-223. doi: 10.3109/10409238009105469.
10
Kinetics of pharmacologic response.药理反应动力学
Pharmacol Ther. 1982;16(2):143-66. doi: 10.1016/0163-7258(82)90051-1.
Zotero 插件